Blog
About

47
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Choosing the Right Tool for the Job: RNAi, TALEN, or CRISPR.

      1 , 2

      Molecular cell

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The most widely used approach for defining gene function is to reduce or completely disrupt its normal expression. For over a decade, RNAi has ruled the lab, offering a magic bullet to disrupt gene expression in many organisms. However, new biotechnological tools--specifically CRISPR-based technologies--have become available and are squeezing out RNAi dominance in mammalian cell studies. These seemingly competing technologies leave research investigators with the question: "Which technology should I use in my experiment?" This review offers a practical resource to compare and contrast these technologies, guiding the investigator when and where to use this fantastic array of powerful tools.

          Related collections

          Author and article information

          Journal
          Mol. Cell
          Molecular cell
          1097-4164
          1097-2765
          May 21 2015
          : 58
          : 4
          Affiliations
          [1 ] Department of Microbiology and Immunology, UCSF Diabetes Center, Keck Center for Noncoding RNA, University of California, San Francisco, San Francisco, CA 94143, USA.
          [2 ] Department of Microbiology and Immunology, UCSF Diabetes Center, Keck Center for Noncoding RNA, University of California, San Francisco, San Francisco, CA 94143, USA. Electronic address: michael.mcmanus@ucsf.edu.
          Article
          S1097-2765(15)00310-X NIHMS684799
          10.1016/j.molcel.2015.04.028
          26000843
          Copyright © 2015 Elsevier Inc. All rights reserved.

          Comments

          Comment on this article